AASLD 2016 Live Coverage

AASLD 2016

Daclatasvir-based Tx Shows High Viral Clearance in Liver Transplant Patients

By November 14, 2016

Researchers reported "high efficacy and an excellent safety profile" for direct-acting antiviral (DAA) combinations with daclatasvir (DCV) among transplanted patients with hepatitis C virus (HCV) infection.

AASLD 2016

SOF-based Regimens Offer New Options for Patients with HCV GT4

By November 14, 2016

Sofosbuvir-based regimens "offer new therapeutic options" for patients with GT4 chroninc hepatitis C virus infection.

AASLD 2016

EBR/GZR+SOF ± RBV is 'Highly Efficacious' for HCV GT3

By November 14, 2016

The EBR/GZR+SOF±RBV regimen is offers "high efficacy" in treating patients with GT3 Hepatitis C Virus (HCV).

AASLD 2016

HCV Treatment Patterns in Patients With Advanced CKD: 2010 to 2015

By November 14, 2016

Data from a retrospective cohort study presented at The Liver Meeting® 2016 has shown that hepatitis C virus (HCV)-infected patients with advanced chronic kidney disease (CKD) "remains a challenging population to treat," with <10% receiving treatment in the early direct-acting antivirals (DAA) era.

AASLD 2016

'MK3' Fixed-Dose Combination Effective in HCV GT 1, 2, and 3

By November 14, 2016

A fixed-dose combination of pangenotypic direct-acting antivirals was "highly effective" in treatment-naïve patients with hepatitis C virus (HCV) genotypes (GT) 1, 2, and 3

AASLD 2016

SOF/VEL/VOX Effective as Retreatment for Non-NS5A DAA Failures

By November 14, 2016

Treatment with single tablet sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for 12 weeks "is a highly effective salvage therapy" for patients who did not previously achieve sustained virologic response (SVR) following treatment with non-NS5A inhibitor-containing direct-acting antivirals (DAAs), results from the POLARIS-4 study presented at The Liver Meeting® 2016 have shown.

AASLD 2016

3-DAA Regimen Studied in HCV With Bridging Fibrosis, Compensated Cirrhosis

By November 14, 2016

3-DAA ± ribavirin achieved high 12-week sustained virologic response rates in Brazilian patients with GT1 hepatitis C virus (HCV) with bridging fibrosis or compensated cirrhosis.

AASLD 2016

Beta-Blockers: No Changes in Heart Rate With Concomitant Sofosbuvir

By November 14, 2016

No clinically significant changes in heart rate or cardiac adverse events were observed in patients with hepatitis C virus (HCV) infection on beta blockers receiving sofosbuvir (SOF)-based regimens, results of a study presented at The Liver Meeting® have found.

AASLD 2016

Opioids Associated With Increased Mortality Among Liver Cirrhosis Patients

By November 14, 2016

Among patients with liver cirrhosis, opioids are associated with increased mortality.

AASLD 2016

Glecaprevir/Pibrentasvir Achieves High SVR12 Rates in Non-cirrhotic HCV GT 4-6

By November 14, 2016

The all-oral, ribavirin-free glecaprevir/pibrentasvir regimen achieved high SVR12 rates in non-cirrhotic patients with hepatitis C virus (HCV) genotype (GT) 4, 5, and 6 infection, the phase 3 ENDURANCE-4 study concluded at The Liver Meeting® 2016.

AASLD 2016 Videos